CN100464785C - 一种抗癌药物缓释注射剂及其应用 - Google Patents
一种抗癌药物缓释注射剂及其应用 Download PDFInfo
- Publication number
- CN100464785C CN100464785C CNB2005100445237A CN200510044523A CN100464785C CN 100464785 C CN100464785 C CN 100464785C CN B2005100445237 A CNB2005100445237 A CN B2005100445237A CN 200510044523 A CN200510044523 A CN 200510044523A CN 100464785 C CN100464785 C CN 100464785C
- Authority
- CN
- China
- Prior art keywords
- injection
- guanine
- benzyl
- solvent
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002347 injection Methods 0.000 title claims abstract description 93
- 239000007924 injection Substances 0.000 title claims abstract description 93
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 71
- 230000001093 anti-cancer Effects 0.000 claims abstract description 31
- 239000000375 suspending agent Substances 0.000 claims abstract description 17
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 12
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims abstract description 7
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims abstract 2
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 32
- 238000013268 sustained release Methods 0.000 claims description 24
- 239000012730 sustained-release form Substances 0.000 claims description 24
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical group NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 18
- 239000011859 microparticle Substances 0.000 claims description 17
- 229960001420 nimustine Drugs 0.000 claims description 17
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 17
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000004626 polylactic acid Substances 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 9
- 229950004403 polifeprosan Drugs 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 239000012747 synergistic agent Substances 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 2
- 229920000305 Nylon 6,10 Polymers 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 42
- 238000000034 method Methods 0.000 abstract description 24
- 239000004005 microsphere Substances 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 18
- 239000000725 suspension Substances 0.000 abstract description 16
- 239000002256 antimetabolite Substances 0.000 abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 5
- 229930195725 Mannitol Natural products 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 239000000594 mannitol Substances 0.000 abstract description 5
- 235000010355 mannitol Nutrition 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 2
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- -1 chrondroitin Polymers 0.000 description 43
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 33
- 229910019142 PO4 Inorganic materials 0.000 description 31
- 239000010452 phosphate Substances 0.000 description 31
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 24
- 229960005524 O6-benzylguanine Drugs 0.000 description 22
- 229940079593 drug Drugs 0.000 description 22
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 229960005243 carmustine Drugs 0.000 description 20
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 15
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 15
- 229960001842 estramustine Drugs 0.000 description 15
- 229960002247 lomustine Drugs 0.000 description 15
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 15
- 229960001924 melphalan Drugs 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 14
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 14
- 229960002707 bendamustine Drugs 0.000 description 14
- 229960001231 choline Drugs 0.000 description 14
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 14
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 14
- 229960004783 fotemustine Drugs 0.000 description 14
- 230000036541 health Effects 0.000 description 14
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 13
- 229960004397 cyclophosphamide Drugs 0.000 description 13
- 229960003440 semustine Drugs 0.000 description 13
- ZLWYEPMDOUQDBW-UHFFFAOYSA-N 6-aminonicotinamide Chemical compound NC(=O)C1=CC=C(N)N=C1 ZLWYEPMDOUQDBW-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 12
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 11
- SPHOZXNZJHRHSL-UHFFFAOYSA-N 6-butoxy-7h-purin-2-amine Chemical compound CCCCOC1=NC(N)=NC2=C1NC=N2 SPHOZXNZJHRHSL-UHFFFAOYSA-N 0.000 description 11
- 229960001052 streptozocin Drugs 0.000 description 11
- 229960004964 temozolomide Drugs 0.000 description 11
- KJQFBVYMGADDTQ-UHFFFAOYSA-N S-butyl-DL-homocysteine (S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 10
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 9
- 229960005192 methoxamine Drugs 0.000 description 9
- 239000005038 ethylene vinyl acetate Substances 0.000 description 8
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 7
- 229930105110 Cyclosporin A Natural products 0.000 description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 7
- 108010036949 Cyclosporine Proteins 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 7
- 229920000954 Polyglycolide Polymers 0.000 description 7
- 150000001335 aliphatic alkanes Chemical class 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 229960001265 ciclosporin Drugs 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 229960000304 folic acid Drugs 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000693 micelle Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N n-hexyl alcohol Natural products CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 7
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 7
- 229950004354 phosphorylcholine Drugs 0.000 description 7
- 235000002949 phytic acid Nutrition 0.000 description 7
- 239000004633 polyglycolic acid Substances 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 7
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 7
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 6
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 6
- 229960004275 glycolic acid Drugs 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012828 PI3K inhibitor Substances 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 5
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 5
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- YJZJEQBSODVMTH-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea Chemical compound OCCNC(=O)N(N=O)CCCl YJZJEQBSODVMTH-UHFFFAOYSA-N 0.000 description 4
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- SEKJSSBJKFLZIT-UHFFFAOYSA-N LSM-1988 Chemical compound C1=CC(CN(C)C)=CC=C1C1=NC2=CC=CC3=C2N1CCNC3=O SEKJSSBJKFLZIT-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000010603 pastilles Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 3
- QRPFYXCKZRCRTD-UHFFFAOYSA-N 4-methyl-5-nitro-6-phenylmethoxypyrimidin-2-amine Chemical compound CC1=NC(N)=NC(OCC=2C=CC=CC=2)=C1[N+]([O-])=O QRPFYXCKZRCRTD-UHFFFAOYSA-N 0.000 description 3
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 3
- DSIVLMKQNTVXOD-UHFFFAOYSA-N 5-nitro-4-phenylmethoxypyrimidin-2-amine Chemical compound NC1=NC=C([N+]([O-])=O)C(OCC=2C=CC=CC=2)=N1 DSIVLMKQNTVXOD-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960001055 uracil mustard Drugs 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- COKGUJJIBXWRNV-CYNREMDZSA-N (3r,4s,5r,6r)-6-[bis(2-chloroethyl)aminomethyl]oxane-2,3,4,5-tetrol Chemical compound OC1O[C@H](CN(CCCl)CCCl)[C@H](O)[C@H](O)[C@H]1O COKGUJJIBXWRNV-CYNREMDZSA-N 0.000 description 2
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 2
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 2
- XWPCYYOZOJKYKQ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-[2-[[2-chloroethyl(nitroso)carbamoyl]amino]ethyldisulfanyl]ethyl]-1-nitrosourea Chemical compound ClCCN(N=O)C(=O)NCCSSCCNC(=O)N(N=O)CCCl XWPCYYOZOJKYKQ-UHFFFAOYSA-N 0.000 description 2
- XIZCDQOKKYYCRH-UHFFFAOYSA-N 1h-benzimidazole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=NC2=C1 XIZCDQOKKYYCRH-UHFFFAOYSA-N 0.000 description 2
- JJDMKDXGNVJWCD-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide Chemical class NC(=O)C1=CC=CC2=C1N=CN2 JJDMKDXGNVJWCD-UHFFFAOYSA-N 0.000 description 2
- CUQJLYFFQBHUGW-UHFFFAOYSA-N 2-(1-methylpiperidin-1-ium-1-yl)ethyl octadecyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+]1(C)CCCCC1 CUQJLYFFQBHUGW-UHFFFAOYSA-N 0.000 description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
- 108091026813 Poly(ADPribose) Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 229930192341 TAN-1518 Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- YASNUXZKZNVXIS-CBNXCZCTSA-N [(3ar,6r,6ar)-4-[[2-chloroethyl(nitroso)carbamoyl]amino]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl 4-nitrobenzoate Chemical compound C([C@@H]1[C@H]2OC(O[C@H]2C(NC(=O)N(CCCl)N=O)O1)(C)C)OC(=O)C1=CC=C([N+]([O-])=O)C=C1 YASNUXZKZNVXIS-CBNXCZCTSA-N 0.000 description 2
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 2
- NRUFLTXGIPFVSH-KBVRNWHJSA-N [(8r,9s,13s,14s,17s)-3-[bis(2-chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] (2s)-2-aminopropanoate Chemical compound C1CC2=CC(OC(=O)N(CCCl)CCCl)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)[C@@H](N)C)[C@@]1(C)CC2 NRUFLTXGIPFVSH-KBVRNWHJSA-N 0.000 description 2
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229950009009 alestramustine Drugs 0.000 description 2
- 229950010949 ambamustine Drugs 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 229950006933 atrimustine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229950003042 bofumustine Drugs 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229950011425 ditiomustine Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229950005678 ecomustine Drugs 0.000 description 2
- 229950003860 elmustine Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 2
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 2
- 229950009429 exatecan Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229950009403 galamustine Drugs 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 2
- 229950008612 mannomustine Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical class C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 2
- ARKYUICTMUZVEW-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229960004694 prednimustine Drugs 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 229960002185 ranimustine Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229950006050 spiromustine Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229950005667 tallimustine Drugs 0.000 description 2
- 108010021891 tallimustine Proteins 0.000 description 2
- 229950010168 tauromustine Drugs 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MTEDBOAIQUHDQD-YNEHKIRRSA-N (2r,3s,5r)-5-(2-amino-6-phenylmethoxypurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C=12N=CN([C@@H]3O[C@H](CO)[C@@H](O)C3)C2=NC(N)=NC=1OCC1=CC=CC=C1 MTEDBOAIQUHDQD-YNEHKIRRSA-N 0.000 description 1
- GVPFIIZZKIULDY-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;sulfane Chemical compound S.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O GVPFIIZZKIULDY-GEMLJDPKSA-N 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- ZATXFBUSDJEEOC-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]-1h-benzimidazole-4-carboxamide Chemical class N=1C=2C(C(=O)N)=CC=CC=2NC=1C1=CC=C(CO)C=C1 ZATXFBUSDJEEOC-UHFFFAOYSA-N 0.000 description 1
- VPMJBCMAJPZWIC-UHFFFAOYSA-N 2-amino-6-phenylmethoxy-7,9-dihydropurin-8-one Chemical compound C=12NC(O)=NC2=NC(N)=NC=1OCC1=CC=CC=C1 VPMJBCMAJPZWIC-UHFFFAOYSA-N 0.000 description 1
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 1
- OBBJGEVEIULNEO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole-4-carboxamide Chemical class N=1C=2C(C(=O)N)=CC=CC=2NC=1C1=CC=CC=C1 OBBJGEVEIULNEO-UHFFFAOYSA-N 0.000 description 1
- IGMMTYZWNUSEEU-UHFFFAOYSA-N 3-(2-chloroethyl)-1-cyclohexyl-1-nitrosourea Chemical compound ClCCNC(=O)N(N=O)C1CCCCC1 IGMMTYZWNUSEEU-UHFFFAOYSA-N 0.000 description 1
- WJXQFVMTIGJBFX-UHFFFAOYSA-N 4-methoxytyramine Chemical compound COC1=CC=C(CCN)C=C1O WJXQFVMTIGJBFX-UHFFFAOYSA-N 0.000 description 1
- KDTRYSQLKJHLTJ-JKGXRCIZSA-N 5-bromo-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-iminopurin-6-one Chemical compound C12=NC(N)=NC(=O)C2(Br)N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 KDTRYSQLKJHLTJ-JKGXRCIZSA-N 0.000 description 1
- XSQWTUFYGIMUNS-UHFFFAOYSA-N 6-chloro-8-methyl-7h-purin-2-amine Chemical compound NC1=NC(Cl)=C2NC(C)=NC2=N1 XSQWTUFYGIMUNS-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- USGXQONHRZESNF-JKGXRCIZSA-N 9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-imino-5-iodopurin-6-one Chemical compound IC12N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(=NC1=O)N USGXQONHRZESNF-JKGXRCIZSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- FTDYFMSUOXZKKR-UHFFFAOYSA-N C(C1=CC(=CC=C1)OC)C1=NC2=C(N1)C=CC=C2C(=O)N Chemical class C(C1=CC(=CC=C1)OC)C1=NC2=C(N1)C=CC=C2C(=O)N FTDYFMSUOXZKKR-UHFFFAOYSA-N 0.000 description 1
- VEKMHZIDYGAWJW-UHFFFAOYSA-N C(CCC)NO.[O] Chemical compound C(CCC)NO.[O] VEKMHZIDYGAWJW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- HXJDWCWJDCOHDG-RYUDHWBXSA-N S-hexylglutathione Chemical compound CCCCCCSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O HXJDWCWJDCOHDG-RYUDHWBXSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- GKFKUZBTGYKBFS-XIHUBIEQSA-N [(2r,3s,4r,5r)-3,4,6-triacetyloxy-5-[[2-chloroethyl(nitroso)carbamoyl]amino]oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(OC(C)=O)[C@H](NC(=O)N(CCCl)N=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O GKFKUZBTGYKBFS-XIHUBIEQSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- ROWSTIYZUWEOMM-UHFFFAOYSA-N chembl488755 Chemical compound C12=CC=CC=C2C(=O)C2=C1C1=CC=C(O)C=C1N=C2NCCN(C)C ROWSTIYZUWEOMM-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- LPRCVLBATUMNBP-UHFFFAOYSA-N decanedioic acid;propane Chemical compound CCC.OC(=O)CCCCCCCCC(O)=O LPRCVLBATUMNBP-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- DZRLVSOGARUEGQ-UHFFFAOYSA-N kinome_3609 Chemical compound C1CN(C)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 DZRLVSOGARUEGQ-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229950010681 neptamustine Drugs 0.000 description 1
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- XKZXGTOMPVMYOS-UHFFFAOYSA-N piperazine;propane Chemical compound CCC.C1CNCCN1 XKZXGTOMPVMYOS-UHFFFAOYSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 1
- 229960002447 thiram Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 78±12 | |
2(6) | O6-BG | 48±5.3 | <0.05 |
3(6) | 尼莫司汀 | 52±2.3 | <0.01 |
4(6) | O6-BG+尼莫司汀 | 38±2.4 | <0.001 |
5(6) | O6-MG | 50±3.0 | <0.01 |
6(6) | 苯达莫司汀 | 46±3.0 | <0.01 |
7(6) | O6-MG+苯达莫司汀 | 22±2.0 | <0.001 |
8(6) | O4-BA | 34±3.6 | <0.01 |
9(6) | 卡莫司汀 | 36±3.8 | <0.01 |
10(6) | O4-BA+卡莫司汀 | 16±2.4 | <0.001 |
瘤细胞 | O6-BuG | O6-AB | 雌莫司汀 | O6-BuG+雌莫司汀 | O6-AB+雌莫司汀 | O6-BA | 洛莫司汀 | O6-BA+洛莫司汀 |
CNS | 66% | 66% | 66% | 86% | 90% | 56% | 56%. | 88% |
C6 | 62% | 64% | 60% | 84% | 96% | 60% | 68% | 94% |
SA | 58% | 60% | 56% | 90% | 86% | 56% | 62% | 92% |
BC | 54% | 64% | 54% | 84% | 94% | 64% | 64% | 82% |
BA | 54% | 60% | 62% | 92% | 98% | 62% | 62% | 90% |
LH | 60% | 58% | 62% | 88% | 90% | 62% | 58% | 84% |
PAT | 56% | 56% | 66% | 86% | 92% | 56% | 58% | 89% |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 82±10 | |
2(6) | 7-氢氧基-星状孢子素 | 48±5.3 | <0.05 |
3(6) | 福莫司汀 | 52±2.3 | <0.01 |
4(6) | 7-氢氧基-星状孢子素+福莫司汀 | 36±2.4 | <0.001 |
5(6) | β-甲氧星状孢子素 | 48±3.0 | <0.01 |
6(6) | 萨莫司汀 | 44±3.0 | <0.01 |
7(6) | β-甲氧星状孢子素+萨莫司汀 | 22±2.0 | <0.001 |
8(6) | 烷基磷酸胆碱 | 32±3.6 | <0.01 |
9(6) | 伊力替康 | 34±3.8 | <0.01 |
10(6) | 烷基磷酸胆碱+伊力替康 | 22±2.6 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 88±2 | |
2(6) | 甲氧胺 | 58±5.8 | <0.05 |
3(6) | 米妥唑胺 | 52±4.3 | <0.01 |
4(6) | 甲氧胺+米妥唑胺 | 36±2.4 | <0.001 |
5(6) | 羟基胺 | 58±3.0 | <0.01 |
6(6) | 环磷酰胺 | 44±3.0 | <0.01 |
7(6) | 羟基胺+环磷酰胺 | 20±2.0 | <0.001 |
8(6) | 丁基硫堇硫肟 | 52±3.6 | <0.01 |
9(6) | 美法仑 | 34±3.8 | <0.01 |
10(6) | 丁基硫堇硫肟+美法仑 | 28±2.6 | <0.001 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100445237A CN100464785C (zh) | 2005-08-30 | 2005-08-30 | 一种抗癌药物缓释注射剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100445237A CN100464785C (zh) | 2005-08-30 | 2005-08-30 | 一种抗癌药物缓释注射剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1923283A CN1923283A (zh) | 2007-03-07 |
CN100464785C true CN100464785C (zh) | 2009-03-04 |
Family
ID=37816226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100445237A Expired - Fee Related CN100464785C (zh) | 2005-08-30 | 2005-08-30 | 一种抗癌药物缓释注射剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100464785C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023033990A1 (en) * | 2021-09-05 | 2023-03-09 | Chien Du Shieng | Formulations with enhanced sn-38 solubility and oral absorption |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1356892A (zh) * | 1999-05-17 | 2002-07-03 | 埃迪克埃迪法姆药品实验室 | 释放抗癌剂的生物降解微球在治疗成胶质细胞瘤方面的用途 |
CN1561988A (zh) * | 2004-03-18 | 2005-01-12 | 山东居仁生物医药技术研究所 | 一种紫杉醇微球抗癌药物的制备方法 |
CN1628851A (zh) * | 2004-10-14 | 2005-06-22 | 孔庆忠 | 抗癌药物组合物 |
CN1628852A (zh) * | 2004-10-14 | 2005-06-22 | 孔庆忠 | 一种抗实体肿瘤药物组合物 |
CN1628850A (zh) * | 2004-10-14 | 2005-06-22 | 孔庆忠 | 一种抗实体肿瘤药物组合物 |
-
2005
- 2005-08-30 CN CNB2005100445237A patent/CN100464785C/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1356892A (zh) * | 1999-05-17 | 2002-07-03 | 埃迪克埃迪法姆药品实验室 | 释放抗癌剂的生物降解微球在治疗成胶质细胞瘤方面的用途 |
CN1561988A (zh) * | 2004-03-18 | 2005-01-12 | 山东居仁生物医药技术研究所 | 一种紫杉醇微球抗癌药物的制备方法 |
CN1628851A (zh) * | 2004-10-14 | 2005-06-22 | 孔庆忠 | 抗癌药物组合物 |
CN1628852A (zh) * | 2004-10-14 | 2005-06-22 | 孔庆忠 | 一种抗实体肿瘤药物组合物 |
CN1628850A (zh) * | 2004-10-14 | 2005-06-22 | 孔庆忠 | 一种抗实体肿瘤药物组合物 |
Non-Patent Citations (4)
Title |
---|
瘤内注射型卡铂缓释微球制备初步研究. 邓伟等.临床超声医学杂志,第5卷第1期. 2003 |
瘤内注射型卡铂缓释微球制备初步研究. 邓伟等.临床超声医学杂志,第5卷第1期. 2003 * |
聚乳酸载药纳米微球的制备及其对脑胶质瘤的抑制研究. 郭艳霜.郭艳霜.聚乳酸载药纳米微球的制备及其对脑胶质瘤的抑制研究.天津大学材料科学与工程学院申请硕士学位论文.二零零四年十二月). 2004 |
聚乳酸载药纳米微球的制备及其对脑胶质瘤的抑制研究. 郭艳霜.郭艳霜.聚乳酸载药纳米微球的制备及其对脑胶质瘤的抑制研究.天津大学材料科学与工程学院申请硕士学位论文.二零零四年十二月). 2004 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023033990A1 (en) * | 2021-09-05 | 2023-03-09 | Chien Du Shieng | Formulations with enhanced sn-38 solubility and oral absorption |
Also Published As
Publication number | Publication date |
---|---|
CN1923283A (zh) | 2007-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101336899A (zh) | 含紫杉烷的抗癌缓释注射剂 | |
CN1857221A (zh) | 一种同载铂类化合物及其增效剂的抗癌缓释剂 | |
CN100464785C (zh) | 一种抗癌药物缓释注射剂及其应用 | |
CN1923171B (zh) | 同载抗癌抗生素及其增效剂的复方抗癌药物缓释剂 | |
CN1846672A (zh) | 一种含抗代谢类药物的抗癌药物组合物 | |
CN100563711C (zh) | 一种抗癌缓释注射剂 | |
CN101385698A (zh) | 一种抗癌缓释植入剂 | |
CN100563710C (zh) | 含嘧啶类似物的抗癌药物缓释剂 | |
CN101292956A (zh) | 含氨甲喋呤及其增效剂的缓释注射剂 | |
CN1875959B (zh) | 一种抗癌药物组合物 | |
CN101244033A (zh) | 含紫杉烷及其增效剂的缓释剂 | |
CN1846670A (zh) | 一种抗癌植入剂 | |
CN100369632C (zh) | 抗癌药物组合物 | |
CN100500220C (zh) | 一种含血管抑制剂的抗实体肿瘤药物组合物 | |
CN101292955A (zh) | 含氟尿嘧啶增效剂的缓释注射剂及其制备方法 | |
CN100500213C (zh) | 含血管抑制剂的抗实体肿瘤药物组合物 | |
CN101371820B (zh) | 含氨甲喋呤增效剂的抗癌缓释剂 | |
CN100594886C (zh) | 一种同载新生血管抑制剂和四唑紫罗兰的抗癌缓释剂 | |
CN100486560C (zh) | 一种含血管抑制剂的复方抗癌缓释注射剂 | |
CN101336900A (zh) | 一种含紫杉烷的抗癌缓释注射剂 | |
CN101244034A (zh) | 一种含紫杉烷及其增效剂的缓释剂 | |
CN1957920B (zh) | 一种同载氟尿嘧啶及其增效剂的抗癌缓释剂 | |
CN100431607C (zh) | 一种抗实体肿瘤的药物组合物 | |
CN101336898A (zh) | 同载铂类药物及其增效剂的抗癌缓释剂 | |
CN101292954A (zh) | 抗癌药物缓释注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG TONGKE TIANDI TECHNOLOGY BUSINESS INCUBAT Free format text: FORMER OWNER: KONG QINGZHONG Effective date: 20140504 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250014 JINAN, SHANDONG PROVINCE TO: 250101 JINAN, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140504 Address after: 250101 Building No. 322, Shun Feng Road, hi tech Zone, Shandong, Ji'nan, 2 Patentee after: Shandong branch of heaven and Earth Technology Business Incubator Co., Ltd. Address before: 250014 Shandong Province, Lixia District of Ji'nan City 2-2 (Yanliu garden) Swallow Hill Road No. 9 Building 2 unit 602 Patentee before: Kong Qingzhong |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181023 Address after: 250101 Room 102, Chunhui Road, hi tech Zone, Ji'nan, Shandong, 102 Patentee after: Shandong Tong Ke supply chain Limited by Share Ltd Address before: 250101 Building 2, Shun Feng Road, Ji'nan high tech Zone, Shandong, China 2 Patentee before: Shandong branch of heaven and Earth Technology Business Incubator Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090304 Termination date: 20190830 |
|
CF01 | Termination of patent right due to non-payment of annual fee |